Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Apathy: full-pipeline trial registry

4 of 7 indexed Apathy trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Apathy: 7 US clinical trials tracked, 4 recruiting.

Apathy is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Medical University of South Carolina, running 2 of these trials.

Enrollment posture brief

Registry condition apathy

OPEN 4 | RECR 57% | LATE 3 | EARLY 2 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Apathy (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Apathy

Apathy lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Apathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Apathy is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Apathy research.

    Medical University of South Carolina accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Apathy trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 7 trials that report a genuine target (sentinel values excluded). 7 of those (100%) plan for fewer than 100 participants.

  4. Apathy research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 31Phase 42

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 3 1
Phase 4 2

Named interventions

Most-linked intervention names on Apathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Neurostar repetitive transcranial magnetic stimulator Device
1 trials
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System Device
1 trials
Wellbutrin XL Drug
1 trials
General Cognitive Training Intervention Behavioral
1 trials
Targeted Cognitive Training Intervention Behavioral
1 trials
Brainsight Neuronavigation System Other
1 trials
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham) Device
1 trials
MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) Device
1 trials

US sites by state

Facility locations filed on Apathy trials. A trial with sites in several states counts in each.

South Carolina 2 trials
New York 1 trials
Louisiana 1 trials
Indiana 1 trials
Florida 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Apathy page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Apathy condition card totals 7 registered trials; most-linked intervention Neurostar repetitive transcranial magnetic stimulator; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.